Brexanolone caprilcerbate

Brexanolone caprilcerbate

Clinical data
Other names	LYT-300; LYT300; SPT-300; SPT300; Allopregnanolone 3-O-caprilcerbate
Routes of administration	Oral [1]
Drug class	GABAA receptor positive allosteric modulator; Neurosteroid
Identifiers
IUPAC name 1-[1,3-bis(octanoyloxy)propan-2-yl] 5-[({[(20-oxo-5α-pregnan3α-yl)oxy]carbonyl}oxy)methyl] 3-methylpentanedioate
CAS Number	2681264-65-1
UNII	K3KLQ9T6WM
Chemical and physical data
Formula	C48H76O12
Molar mass	845.124 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CC(C)CC(=O)OCOC(=O)O[C]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]4CC[C](C(C)=O)[C@@]4(C)CC[C@H]23)C1
InChI InChI=1S/C48H76O12/c1-7-9-11-13-15-17-42(50)55-30-37(31-56-43(51)18-16-14-12-10-8-2)59-45(53)28-33(3)27-44(52)57-32-58-46(54)60-36-23-25-47(5)35(29-36)19-20-38-40-22-21-39(34(4)49)48(40,6)26-24-41(38)47/h33,35,37-38,40-41H,7-32H2,1-6H3/t33?,35-,38-,40-,41-,47-,48+/m0/s1 Key:CBBCXTNYOFUFEZ-RMCIIBJBSA-N

Brexanolone caprilcerbate (INN Tooltip International Nonproprietary Name; developmental code names LYT-300, SPT-300) is an orally active prodrug of brexanolone (allopregnanolone) which is under development for the treatment of anxiety disorders. ^{[1] [2] [3] [4]} It is a absorbed via the lymphatic system with oral administration. ^[5] The drug is being developed by Seaport Therapeutics and PureTech Health. ^{[1] [2]} As of January 2025, it is in phase 2 clinical trials. ^[1]

See also

• List of investigational anxiolytics

References

1. "Allopregnanolone prodrug". AdisInsight. 28 January 2025. Retrieved 26 February 2025.
2. "Delving into the Latest Updates on Brexanolone caprilcerbate with Synapse". Synapse. 15 February 2025. Retrieved 26 February 2025.
3. "Proposed INN: List 131 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 38 (2): 270. 2024. brexanolonum caprilcerbas brexanolone caprilcerbate 1-[1,3-bis(octanoyloxy)propan-2-yl] 5-[({[(20-oxo-5α-pregnan3α-yl)oxy]carbonyl}oxy)methyl] 3-methylpentanedioate GABAA receptor positive allosteric modulator C48H78O12 2681264-65-1
4. Carlini SV, Osborne LM, Deligiannidis KM (December 2023). "Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression". Dialogues in Clinical Neuroscience. 25 (1): 92–100. doi:10.1080/19585969.2023.2262464. PMC   10557560 . PMID   37796239.
5. Alashal N, Hussain N (2025). "Approach to the use of rescue medications in children for prolonged epileptic seizures in the community". Paediatrics and Child Health. doi:10.1016/j.paed.2025.01.004.